Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study

被引：0
|
作者：
Oaknin, Ana [1 ]
Pothuri, Bhavana [2 ,3 ]
Gilbert, Lucy [4 ]
Sabatier, Renaud [5 ]
Ghamande, Sharad [6 ]
Gravina, Adriano [7 ]
Calvo, Emiliano [8 ]
Banerjee, Susana [9 ,10 ]
Mangan, Niamh [11 ]
Miller, Rowan E. [12 ]
Pikiel, Joanna [13 ]
Mirza, Mansoor R. [14 ]
Duan, Tao [15 ]
Zildjian, Sybil [16 ]
Zografos, Eleftherios [17 ]
Veneris, Jennifer [16 ]
Tinker, Anna V. [18 ]
机构：
[1] Hosp Univ Vall dHebron, Gynaecol Canc Programme, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[2] NYU Langone Hlth, Gynecol Oncol Grp GOG, New York, NY USA
[3] NYU Langone Hlth, Dept Obstet Gynecol, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[4] McGill Univ, Div Gynecol Oncol, Hlth Ctr, Montreal, PQ, Canada
[5] Aix Marseille Univ, Dept Med Oncol, Marseille, France
[6] Augusta Univ, Dept Obstet & Gynecol, Georgia Canc Ctr, Augusta, GA USA
[7] Ist Nazl Tumouri Fdn G Pascale, Clin Trial Unit, Naples, Italy
[8] Ctr Integral Oncol Clara Campal, START Madrid CIOCC, Madrid, Spain
[9] Royal Marsden NHS Fdn Trust, London, England
[10] Inst Canc Res, London, England
[11] GSK, Melbourne, Australia
[12] UCL, St Bartholomews Hosp London, London, England
[13] Reg Ctr Oncol, Dept Chemotherapy, Gdansk, Poland
[14] Rigshosp, Copenhagen Univ Hosp, Nord Soc Gynaecol Oncol Clin Trial Unit, Dept Oncol, Copenhagen, Denmark
[15] GSK, Pennington, NJ USA
[16] GSK, Waltham, MA USA
[17] GSK, London, England
[18] Univ British Columbia, Dept Med, British Columbia Canc, Vancouver Ctr, Vancouver, BC, Canada
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
218
引用
收藏
页码：133 / 134
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLε)-mutated solid tumours in the GARNET study
    Samuel, L.
    Miller, R.
    Ross, P.
    Arkenau, T.
    Antony, G.
    Veneris, J.
    Rule, J.
    Starling, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S73 - S74
  • [22] Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
    Maio, M.
    Ascierto, P. A.
    Motola Kuba, D.
    Penel, N.
    Cassier, P. A.
    Bariani, G. M.
    De Jesus-Acosta, A.
    Doi, T.
    Longo Munoz, F.
    Miller, W. H.
    Oh, D-Y.
    Gottfried, M.
    Yao, L.
    Jin, F. J.
    Gozman, A.
    Marabelle, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S589 - S590
  • [23] PEMBROLIZUMAB MONOTHERAPY FOR MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) RECURRENT GLIOMAS: RESULTS FROM THE MULTICOHORT PHASE 2 KEYNOTE-158 STUDY
    Baldini, Capucine
    Cassier, Philippe A.
    Delord, Jean-Pierre
    Simonelli, Matteo
    Touat, Mehdi
    Yao, Lili
    Duic, J. Paul
    Gozman, Alexander
    Marabelle, Aurelien
    NEURO-ONCOLOGY, 2022, 24 : 59 - 60
  • [24] On pembrolizumab (Keytruda) in microsatellite instability-high/mismatch repair deficient (MSI-h/MMRd) metastatic colorectal cancer (mCRC)
    Bekaii-Saab, Tanios S.
    ONCOLOGY-NEW YORK, 2021, 35 (07): : 380 - 380
  • [25] Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile.
    Mohamed, A. M. R.
    Jiang, Renjian
    Philip, Philip Agop
    Diab, Maria
    Behera, Madhusmita
    Wu, Christina
    El-Rayes, Bassel F.
    Akce, Mehmet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab.
    Kristeleit, Rebecca Sophie
    Mathews, Cara Amanda
    Redondo, Andres
    Huang, Joice
    Eliason, Laurie
    Im, Ellie
    Brown, Jubilee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review
    Lorenzi, Maria
    Amonkar, Mayur
    Zhang, Jacky
    Mehta, Shivani
    Liaw, Kai-Li
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [28] Patient-reported outcomes (PRO) in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab in the GARNET trial.
    Kristeleit, Rebecca Sophie
    Mathews, Cara Amanda
    Redondo, Andres
    Huang, Joice
    Eliason, Laurie
    Im, Ellie
    Brown, Jubilee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [29] Systematic literature review (SLR) of prognostic factors (PFs) in locally advanced rectal cancer (LARC) and mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer (RC).
    Capdevila, Jaume
    O'Donnell, Sean
    Borkowska, Katarzyna
    Frampton, James
    Betts, Marissa
    Maierhofer, Courtney
    Kalilani, Linda
    Garside, Jamie
    Wang, Huifen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 303 - 303
  • [30] STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS
    Lorenzi, M.
    Amonkar, M.
    Zhang, J.
    Mehta, S.
    Liaw, K.
    VALUE IN HEALTH, 2018, 21 : S22 - S23
12345